PO.CH03.01 · 化学
ADGRL4 的冷冻电镜结构为其激活机制提供了功能性见解
The cryo-EM structure of ADGRL4 provides functional insights into its mechanism of activation
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
背景
ADGRL4(也称为 ELTD1)是一种孤儿黏附型 G 蛋白偶联受体(aGPCR),在多种侵袭性恶性肿瘤中上调,促进血管生成、增殖和上皮-间质转化。然而,其分子激活机制此前尚不清楚。我们证明 ADGRL4 与异三聚体 G 蛋白 Gq 弱偶联,并确定了 ADGRL4 的首个活性态冷冻电镜结构。随后我们将结构数据与系统性诱变和 G 蛋白募集分析相结合,以定义系留激动剂(TA)介导激活的分子决定因素。
方法
使用工程化 ADGRL4 和 mini-G 蛋白构建体的分裂 NanoLuc 邻近分析来定量 Gq 偶联。我们纯化了活性态 ADGRL4-mini-Gq-βγ 复合物,并通过冷冻电镜确定了其结构。在结构指导下,我们对接触正构结合口袋的 TA 残基和受体核心内的选定残基进行了丙氨酸扫描诱变,评估其对 HEK293T 细胞中 Gq 募集的影响。
结果
冷冻电镜分析获得了活性态 ADGRL4 的首个高分辨率结构,分辨率达 3.1 Å。TA 区域形成一个短 α 螺旋,占据正构位点并促进跨膜螺旋 6(TM6)的向外位移。与正构口袋相互作用的八个 TA 残基中,七个的丙氨酸替换显著损害了 Gq 募集。六个残基(H408A、F409A、I411A、L412A、M413A、S414A)的突变使偶联减少 >50%;M413A 完全消除偶联(p<0.0001),F409A 使偶联减少 88%(p<0.0001)。此前的 aGPCR 结构提出了三个保守的核心激活基序:上四级核心基序(UQC)、疏水性 P/F/W/LφφG 基序和 H(N)L(M)Y 基序。对 ADGRL4 中相应位置进行结构指导的诱变表明,任何 UQC 残基突变为丙氨酸(F505A、M508A、W631A)均可消除 Gq 募集。在 P/F/W/LφφG 基序中,L627A 和 G628 消除活性,而 F625A 和 L626A 引起部分损害。在 H(N)L(M)Y 基序中,L515A 和 Y516A 消除偶联,而 H514A 引起部分损害。总之,这些发现阐明了 ADGRL4 的激活机制:TA 的暴露允许其与正构口袋结合,进而促进 TM6 位移并形成用于 Gq 结合的胞质裂隙,所有激活基序均作为该过程的必需结构元件发挥作用。
结论
这些发现定义了 ADGRL4 的 TA 和保守的 7TM 激活基序如何协同稳定其活性构象并结合 Gq。这些发现为开发 ADGRL4 选择性拮抗剂(纳米抗体、合成结合物或小分子)建立了结构框架,在 ADGRL4 相关恶性肿瘤中具有潜在治疗价值。
查看英文原文 English abstract
Background
ADGRL4 (also known as ELTD1) is an orphan adhesion G protein-coupled receptor (aGPCR) upregulated in multiple aggressive malignancies where it promotes angiogenesis, proliferation and epithelial-mesenchymal transition. Its molecular activation mechanism however was previously unknown. We demonstrated that ADGRL4 couples weakly to the heterotrimeric G protein G q and determined the first active-state cryo-EM structure of ADGRL4. We then combined the structural data with systematic mutagenesis and G protein recruitment assays to define the molecular determinants of tethered agonist (TA) mediated activation.
Methods
A split NanoLuc-proximity assay using engineered ADGRL4 and mini-G protein constructs was used to quantitate Gq coupling. We purified the active-state ADGRL4-mini-G q -betagamma complex and determined its structure by cryo-EM. Guided by the structure, we performed alanine-scanning mutagenesis on TA residues contacting the orthosteric binding pocket and selected residues within the receptor core, assessing effects on G q recruitment in HEK293T cells.
Results
Cryo-EM analysis yielded the first high-resolution structure of active-state ADGRL4 to 3.1 Å resolution. The TA region forms a short alpha-helix that occupies the orthosteric site and promotes outward displacement of transmembrane helix 6 (TM6). Alanine substitution of seven out of eight TA residues that interact with the orthosteric pocket significant impaired G q recruitment. Mutation of six residues (H408A, F409A, I411A, L412A, M413A, S414A) reduced coupling by >50%; M413A abolished coupling completely ( p <0.0001) and F409A reduced coupling by 88% ( p <0.0001). Previous aGPCR structures have proposed three conserved core activation motifs: the upper quaternary core motif (UQC), the hydrophobic P/F/W/LφφG motif, and the H(N)L(M)Y motif. Structure-guided mutagenesis of corresponding positions in ADGRL4 showed that mutation of any UQC residue to alanine (F505A, M508A, W631A) abolished G q recruitment. In the P/F/W/LφφG motif, L627A and G628 eliminated activity, whilst F625A and L626A caused partial impairment. In the H(N)L(M)Y motif, L515A and Y516A abolished coupling, whilst H514A produced partial impairment. Together, these findings clarify ADGRL4's activation mechanism: exposure of the TA permits engagement with the orthosteric pocket, which in turns facilitates TM6 displacement and formation of a cytoplasmic cleft for G q engagement, with all activation motifs functioning as essential structural elements of this process.
Conclusions
These findings define how ADGRL4's TA and conserved 7TM activation motifs cooperatively stabilise its active conformation and engage G q . These findings establish a structural framework for developing ADGRL4-selective antagonists (nanobodies, synthetic binders or small molecules) with potential therapeutic utility in ADGRL4-associated malignancies.
利益披露 Disclosure
D. M. Favara, None..
Q. Chen, None..
A. Gusach, None.
A. Diamante,
Nxera Pharma UK Limited Employment.
J. C. Patel,
Nxera Pharma UK Limited Employment.
P. C. Edwards, None.
C. G. Tate,
Nxera Pharma UK Limited Stock.